



Docket No. 3842-4050

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AUG 14 2003

Applicant(s): Francis Michon, et al.

Group Art Unit: 1645

TECH CENTER 1600/2900

Serial No.: 09/853,367

Examiner: S. Devi

Filed: May 11, 2001

For: IMMUNOGENIC COMPOSITIONS OF LOW MOLECULAR WEIGHT
HYALURONIC ACID AND METHODS TO PREVENT, TREAT AND
DIAGNOSE INFECTIONS AND DISEASES CAUSED BY GROUP A AND
GROUP C STREPTOCOCCI

EXPRESS MAIL CERTIFICATE

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Express Mail Label No.: EV 245491849 US

Date of Deposit: August 11, 2003

I hereby certify that the following attached paper(s) and/or fee

1. Information Disclosure Statement (3 pages);
2. Form PTO 1449 (1 page);
3. Copies of documents cited in Form PTO-1449 including Search Report (6 total documents);
4. Check in the amount of \$180.00; and
5. Return receipt postcard.

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Ron London
(Typed or printed name of person mailing paper(s) and/or fee)

(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile

Express Mail No. EV 245491849 US



08-12-03

1645/4
P#10
Docket No. 3842-4050

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Francis Michon, et al.

Group Art Unit: 1645

Serial No.: 09/853,367

Examiner: S. Devi

Filed: May 11, 2001

For: IMMUNOGENIC COMPOSITIONS OF LOW MOLECULAR WEIGHT HYALURONIC ACID AND METHODS TO PREVENT, TREAT AND DIAGNOSE INFECTIONS AND DISEASES CAUSED BY GROUP A AND GROUP C STREPTOCOCCI

INFORMATION DISCLOSURE STATEMENT

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:

JP 09 012600 A

2. For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
3. Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. _____, filed _____.
4. No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:
 - 37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or

08/13/2003 KBETEHAI 00000026 09853367

Express Mail No. EV 245491849 US

784885 v1 01806

180.00 0P

Serial No. 09/853,367

- 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
- 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
- 37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.

5. No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.

6. A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):

- A check in the amount of \$180.00 is enclosed in payment of the fee.
- Charge the fee to Deposit Account No. 13-4500, Order No. . A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

7. A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:

- a. one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and
- b. the fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 below.

8. A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:

- a. 37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);

Serial No. 09/853,367

b. 37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).

c. The fees due under 37 C.F.R. §§1.17(h) and 1.17(p) are paid as set forth in paragraph 11 below.

9. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.


I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

10. This document is accompanied by a Search Report Communication which was cited in a corresponding PCT or Foreign counterpart application

11. A check in the amount of \$180.00 is enclosed in payment of the fees due under 37 C.F.R. §§1.17(h) and 1.17(p).

Charge the fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 13-4500, Order No. _____. A DUPLICATE COPY OF THIS SHEET THIS ATTACHED.

The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3842-4050. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

By: _____
Evelyn M. Kwon
Registration No. 54,246

Dated: August 11, 2003

Correspondence Address:
MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



TRADEMA
FORM PTO-1449
INFORMATION DISCLOSURE CITATION

Attorney Docket: Serial No.:
3842-4050 09/853,367

Applicant:
Francis Michon, et al.

Filing Date:

Francis Michon, Jr.
Filing Date: May 11, 2001 Group Art Unit: 1645

U.S. PATENT DOCUMENTS

RECEIVED
1994

AUG 14 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, etc.)

OTHER DOCUMENTS (Including Author, Title, Date, etc.)

O'Hagan, DT, *Journal of Pharmacy and Pharmacology*, "Recent Advances In Vaccine Adjuvants For Systemic And Mucosal Administration" Vol. 49, No. 1, January 1998, pp 1-10.

Yamada, T, *Journal of Immunology*, "Immunogenic Activity Of Hapten Conjugated

Humphrey, JH, European Journal of Immunology, "Tolerogenic Or Immunogenic Activity Of Hapten Conjugated Polysaccharides Correlated With Cellular Localization" Vol. 11, No. 3, 1981, pp 212-220.

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.